June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH EPLERENONE OR PHOTODYNAMIC THERAPY
Author Affiliations & Notes
  • Alessandro Rabiolo
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Ilaria Zucchiatti
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • alessandro marchese
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Giovanni Baldin
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Riccardo Sacconi
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Daniela Montorio
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Maria Vittoria Cicinelli
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Lea Querques
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Giuseppe Querques
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Francesco Bandello
    Department of Ophthalmology, San Raffaele Scientific Institute, Milan, Italy
  • Footnotes
    Commercial Relationships   Alessandro Rabiolo, None; Ilaria Zucchiatti, None; alessandro marchese, None; Giovanni Baldin, None; Riccardo Sacconi, None; Daniela Montorio, None; Maria Vittoria Cicinelli, None; Lea Querques, None; Giuseppe Querques, Alcon (C), Alimera (C), Allergan (C), Bausch and Lomb (C), Bayer (C), Novartis (C), Ophthotech (C); Francesco Bandello, Alimera (C), Allergan (C), Bayer (C), Farmila-thea (C), Genetech (C), Hoffman-Laroche (C), Novagali (C), Novartis (C), Pharma (C), Sanofi aventis (C), Schering pharma (C)
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 1645. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Alessandro Rabiolo, Ilaria Zucchiatti, alessandro marchese, Giovanni Baldin, Riccardo Sacconi, Daniela Montorio, Maria Vittoria Cicinelli, Lea Querques, Giuseppe Querques, Francesco Bandello; OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY IN CENTRAL SEROUS CHORIORETINOPATHY TREATED WITH EPLERENONE OR PHOTODYNAMIC THERAPY. Invest. Ophthalmol. Vis. Sci. 2017;58(8):1645.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : To correlate function and structural optical coherence tomography (OCT) to optical coherence tomography angiography (OCT-A) measures in patients affected by central serous chorioretinopathy (CSC) and to describe their changes after treatments (i.e. oral eplerenone, half-fluence photodynamic therapy [PDT]).

Methods : Twenty eyes of 16 consecutive patients with treatment-naïve CSC undergoing either eplerenone or PDT were enrolled in this prospective, observational study. All patients underwent structural OCT and OCT-A at baseline and after therapy at months 1 and 3.

Results : Eleven eyes of 9 patients and 9 eyes of 7 patients underwent eplerenone or PDT treatment, respectively. Central macular thickness (CMT) and subretinal fluid (SRF) correlated to fovea avascular zone (FAZ) area (r = 0.74 and r = 0.71, p = 0.01) and vessel density (r = 0.77 and r = 0.68, p = 0.01) at deep capillary plexus (DCP). CMT (p = 0.0011), SRF (p = 0.0005), SFCT (p = 0.0016), FAZ area at DCP (p = 0.0334) improved at 3-month visit. A significant reduction of deep FAZ area was appreciated in Eplerenone (p = 0.0204) but not in PDT (p = 0.5) group. SFCT reduction was significantly higher in PDT than eplerenone group (p = 0.0347).

Conclusions : Structural and vascular parameters are correlated in CSC and they improve after different treatments. Both half-fluence PDT and oral eplerenone do not permanently damage choriocapillaris or other choroidal layers as evaluated by OCT-A. SFCT decreases with both treatments, although the change is more pronounced following half-fluence PDT.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×